New Report on Worldwide Enteric Disease Testing Market to Cross $6.1 Billion in 2027

The worldwide market for enteric disease testing is steadily increasing by 5.5% CAGR, driven by demand for early detection, prognosis & wider applications.

Online PR News – 07-May-2020 – April 5, 2020, Maryland Heights, Missouri – Gastrointestinal pathogens profoundly affect human health and well being. Multiple clinical and laboratory factors need to be considered when attempting to diagnose the wide variety of gastrointestinal pathogens afflicting humans. Recent advances involve improved polymerase chain reaction assays and other technology applications to a broader range of pathogens, antigen assays, and improved culture techniques.

The emergence of various advance cost effective technologies such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) are expected to boost the growth of enteric disease testing market. Similarly, the nucleic acid amplification tests (NAAT) for viruses are well established as the gold standard, and an increasing number of commercial multi-target assays are now available for bacteria and parasites. Laboratory-based surveillance provides crucial information for assessing food-borne disease trends. However, because only a small proportion of illnesses are diagnosed and reported, periodic assessments of total episodes of illness are also needed.

The recently published iHealthcareAnalyst report on worldwide enteric disease testing market estimates the market size (USD million 2017 to 2027), market share, growth trends and forecast (CAGR% 2020 to 2027). Moreover, the global market is segmented by causal organism [bacterial agents (Clostridium difficile, Campylobacteriosis, cholera, E. coli, H. pylori, salmonellosis, shigellosis); viral agents (norovirus, rotavirus); parasitic agents (amebiasis, cryptosporidiosis, giardiasis)], and geography. Among all the causal organisms, giardiasis parasitic agent segment dominated the global market, whereas cholera bacterial infection segment anticipated to witness the fastest growth rate throughout the coming years.

The global market research report is segmented into geography as North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World. North America and European regions having maintained a high level of hygiene and sanitation infrastructure have observed very low levels of enteric disease epidemics and incidences.

Major companies in the worldwide enteric disease diagnostics market are Abbott Laboratories, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad Laboratories, Inc., Coris BioConcept SPRL, Danaher Corporation (Cepheid, Inc.), DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Inc., and Trinity Biotech plc.

The report detail information is available at

Causal Organism
Bacterial Agents
Clostridium difficile Infection
E. coli Infection
H. pylori Infection
Viral Agents
Norovirus Infection
Rotavirus Infection
Parasitic Agents

Geography / Country-wise Markets
North America (U.S., Canada)
Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
Asia Pacific (Japan, China, India, Rest of APAC)
Latin America (Brazil, Mexico, Rest of LA)
Rest of the World

Companies Listed
Abbott Laboratories, Inc.
Becton, Dickinson & Company
Biomerica, Inc.
bioMérieux S.A.
Bio-Rad Laboratories, Inc.
Coris BioConcept SPRL
Danaher Corporation (Cepheid, Inc.)
Diasorin S.p.A.
Meridian Bioscience, Inc.
Quest Diagnostics, Inc.
Trinity Biotech plc

To request Table of Contents and Sample Pages of this report visit: